Equities

MaxCyte Inc

MXCT:LSE

MaxCyte Inc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)297.00
  • Today's Change2.00 / 0.68%
  • Shares traded2.49k
  • 1 Year change-22.86%
  • Beta--
Data delayed at least 20 minutes, as of May 02 2024 17:07 BST.
More ▼

Profile data is unavailable for this security.

About the company

MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.

  • Revenue in USD (TTM)41.29m
  • Net income in USD-37.92m
  • Incorporated1998
  • Employees143.00
  • Location
    MaxCyte Inc9713 KEY WEST AVENUE,, SUITE 400ROCKVILLE 20850United StatesUSA
  • Phone+1 (301) 517-5556Fax+1 (301) 944-1703
  • Websitehttps://www.maxcyte.com/
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.